1P-ETH-LAD
1P-ETH-LAD is a semisynthetic psychedelic of the lysergamide class and a suspected prodrug of ETH-LAD1, structurally related to both LSD and 1P-LSD. Developed as a designer drug, it is reported to be moderately to significantly more potent than LSD. Its effects are often described as more visual and synaesthetic, with a deeper, less emotionally-charged headspace. It remains largely unresearched1 and is classified as a research chemical.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
Cognitive
Visual
Distortions
Hallucinatory States
1P-ETH-LAD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics. These effects include:
Auditory
by Josie KinsAugust 2016.Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
1P-ETH-LAD likely acts as a partial agonist at serotonin 5-HT2A receptors, which are believed to mediate its psychedelic effects. It shares a similar mechanism of action with its parent compound LSD and appears to be roughly equal in potency. Research demonstrating the formation of ETH-LAD from 1P-ETH-LAD in human serum suggests that it may function as a prodrug, with ETH-LAD serving as the active compound.1
Pharmacokinetics
1P-ETH-LAD has been shown to convert to ETH-LAD when incubated in human serum, suggesting it functions as a prodrug.1 The progression and duration of its effects are compressed relative to LSD, which is suspected to reflect differences in metabolism.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Tolerance
Serotonergic psychedelics, Tryptamines, Lysergamides
Harm Potential
Addiction & Dependence
Psychosis Risk
Delusions are listed among possible cognitive effects during the experience. No quantified data exists on standalone psychosis risk.
History & Culture
1P-ETH-LAD emerged on the research chemical market in early 2016, with virtually no documented history of human usage prior to January of that year. The compound appeared alongside other novel lysergamide derivatives such as 1P-LSD and ETH-LAD, marketed primarily through online research chemical…
Legality
By Country
References
Source Pages
Citations
- (n.d.). It is the 1- propionyl chemical derivative|derivative of ETH-LAD and is thought to act as a prodrug of ETH-LAD analogously to how 1P-LSD acts as a prodrug of LSD. https://doi.org/10.1002/dta.219612345
- David E Nichols. (2016). Psychedelics. 68(2), 264-355. https://doi.org/10.1124/pr.115.01147812
- Anne K Schlag, Jacob Aday, Iram Salam, Jo C Neill, & David J Nutt. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. 36(3), 258-272. https://doi.org/10.1177/0269881121106910012
- (n.d.). Anlage 1 NpSG (Stoffgruppen), Gruppe 5.2 Delta-9,10-Ergolene. gesetze-im-internet.de. https://www.gesetze-im-internet.de/npsg/anlage_1.html1
- (n.d.). Änderungen an Neue-psychoaktive-Stoffe-Gesetz (NpSG) – chronologische Übersicht. buzer.de. https://www.buzer.de/gesetz/12250/l.htm1
- (2019). § 4 NpSG. https://www.gesetze-im-internet.de/npsg/__4.html12
- (n.d.). § 3 NpSG - Unerlaubter Umgang mit neuen psychoaktiven Stoffen. gesetze-im-internet.de. https://www.gesetze-im-internet.de/npsg/__3.html1
- (2019). Cumhurbaşkanı Kararı: Karar Sayısı: 1335. https://resmigazete.gov.tr/eskiler/2019/07/20190720-19.pdf1
- (n.d.). Psychoactive Substances Act 2016. Legislation.gov.uk. http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted123
- (n.d.). The Psychoactive Substances Act 2016 (Commencement) Regulations 2016 (SI 2016/553). Legislation.gov.uk. https://www.legislation.gov.uk/uksi/2016/553/made1
- (n.d.). 21 U.S. Code § 812 - Schedules of controlled substances. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/21/8121
- (n.d.). 21 U.S. Code § 813 - Treatment of controlled substance analogues. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/21/8131
- (n.d.). 21 U.S. Code § 802 - Definitions (controlled substance analogue, para. 32). Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/21/8021
Further Reading
- Reviewed & approved
Reviewed, edited, and approved by subject-matter expert Lyrea.
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 1P-ETH-LAD article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.